Top Markets
Coin of the day
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
Peringkat dalam Saham #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
Harga Saham
$9.60
Terakhir disinkronkan: 2025-05-21
Kapitalisasi Pasar
$1.08B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan OptiNose, Inc. (OPTN)

Kategori

Rasio P/B untuk OptiNose, Inc. (OPTN)
Rasio P/B per August 2026 TTM: -2.42
Menurut laporan keuangan dan harga saham terbaru dari OptiNose, Inc., rasio P/B saat ini (TTM) adalah -2.42. Pada akhir 2023, rasio P/B perusahaan adalah -25.04.
Riwayat rasio P/B untuk OptiNose, Inc. dari 2015 hingga 2026
Rasio P/B pada akhir setiap tahun
Tahun Rasio P/B Mengubah
2026 (TTM) -2.42 43.80%
2024 -1.68 -93.29%
2023 -25.04 792.27%
2022 -2.81 -95.58%
2021 -63.45 -114.37%
2020 441.64 369.60%
2019 94.05 201.63%
2018 31.18 -49.24%
2017 61.42 -130.42%
2016 -201.90 -28.02%
2015 -280.48 0.00%
Rasio P/B untuk perusahaan sejenis atau pesaing